A case of resected huge ileocolonic mesenteric liposarcoma which responded to pre-operative chemotherapy using doxorubicin, cisplatin and ifosfamide

被引:8
作者
Ishiguro, Seiji [1 ]
Yamamoto, Seiichiro [1 ]
Chuman, Hirokazu [1 ]
Moriya, Yoshihiro [1 ]
机构
[1] Natl Canc Ctr, Colorectal Surg Div, Tyuo Ku, Tokyo 1040045, Japan
关键词
mesenteric liposarcoma; preoperative chemotherapy; doxorubicin; ifosfamide;
D O I
10.1093/jjco/hyl087
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Primary mesenteric liposarcoma is a rare entity that has been reported only 14 times in English literature. The treatment strategy for mesenteric liposarcoma is, if no distant metastases are detected, surgical resection with a wide surgical margin, often followed by radiation and/or adjuvant chemotherapy for high-risk patients. However, the efficacy of pre-operative chemotherapy is unknown. If the tumor is shrunk by pre-operative chemotherapy, we could achieve complete surgical resection, which is difficult when the tumor is too large or is invading neighboring organs. We herein describe a case of huge mesenteric liposarcoma that showed significant tumor shrinkage by pre-operative chemotherapy using doxorubicin, cisplatin and ifosfamide, allowing a margin-negative operation.
引用
收藏
页码:735 / 738
页数:4
相关论文
共 34 条
[1]  
Amato G, 1998, HEPATO-GASTROENTEROL, V45, P2151
[2]  
BACCI G, 1993, CANCER, V72, P3227, DOI 10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO
[3]  
2-C
[4]  
BENJAMIN RS, 1993, CANCER CHEMOTH PHARM, V31, pS174
[5]  
CASPER ES, 1994, CANCER, V73, P1644, DOI 10.1002/1097-0142(19940315)73:6<1644::AID-CNCR2820730616>3.0.CO
[6]  
2-V
[7]   High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: Is it feasible? [J].
De Pas, T ;
De Braud, F ;
Orlando, L ;
Nole, F ;
Munzone, E ;
Zampino, MG ;
Fazio, N ;
Aapro, MS ;
Goldhirsch, A .
ANNALS OF ONCOLOGY, 1998, 9 (08) :917-919
[8]  
EDMONSON JH, 1985, CANCER CHEMOTH PHARM, V15, P181
[9]   Retroperitoneal sarcomas. [J].
Eilber F.C. ;
Eilber K.S. ;
Eilber F.R. .
Current Treatment Options in Oncology, 2000, 1 (3) :274-278